(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3-(2-aminoethylcarbamoyloxy)-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid | 1040307-83-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3-(2-aminoethylcarbamoyloxy)-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• CAS: 1040307-83-2
• 化学式: C₂₇H₄₆N₂O₅
• 分子量: 478.673
• InChiKey: UELXXPIQPJNJQI-IOJOMAJISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  122
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethyl-3-(4-nitrophenoxy)carbonyloxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid 、 乙二胺 在 N-甲基吗啉 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3-(2-aminoethylcarbamoyloxy)-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
  参考文献：
  名称：

  胆汁酸靶向透明质酸纳米颗粒可增强去铁胺的口服吸收

  摘要：

  β地中海贫血和镰状细胞病患者经常依赖输血，这可能导致血色素沉着症和细胞和组织的慢性氧化应激。去铁胺 (DFO) 已被临床批准用于治疗血色素沉着症，但由于其药代动力学较差，需要长期输注方案，因此对患者来说效果不佳。尽管口服途径是优选的，但 DFO 的口服生物利用度有限。研究表明，透明质酸（HA）和胆汁酸（BA）可以增强吸收不良药物的口服吸收。为了改进 DFO 的口服给药，我们报告了与两种类型的 BA、脱氧胆酸 (DOCA) 和牛磺胆酸 (TCA) 以及 DFO 缀合的 HA (MW 15 kD) 的合成和表征。所得的七种聚合物缀合物均形成自组装纳米颗粒。通过核磁共振、傅里叶变换红外光谱和紫外-可见光谱证实了 BA 和 DFO 与 HA 聚合物的结合程度。根据理化特性确定了用于进一步体外测试的最佳配方，其中包括 HA-DFO、TCA 9 -HA-DFO 和 DOCA 9 -HA-DFO。体外测定结果表明，与游离药物

  DOI：

  10.1208/s12248-024-00911-z

文献信息

• Imaging of the GI tract by QDs loaded heparin–deoxycholic acid (DOCA) nanoparticles
  作者：Zehedina Khatun、Md. Nurunnabi、Kwang Jae Cho、Yong-kyu Lee

  DOI：10.1016/j.carbpol.2012.07.016

  日期：2012.11

  This study presents an approach to deliver non invasive, near-IR imaging agent using oral delivery system. Low molecular weight heparin (LMWH)-deoxycholic acid (DOCA)/(LHD) nanoparticles formed by a self-assembly method was prepared to evaluate their physicochemical properties and oral absorption in vitro and in vivo. Near-IR QDs were prepared and loaded into LHD nanoparticles for imaging of the gastro-intestinal (Cl) tract absorption. Q-LHD nanoparticles were almost spherical in shape with diameters of 194-217 nm. The size and fluorescent intensity of the Q-LHD nanoparticles were stable in 10% FBS solution and retained their fluorescent even after 5 days of incubation. Cell viability of Q-LHD nanoparticles maintained in the range of 80-95% for 24h incubation. No damage was found in tissues or organs during animal experiments. The in vivo oral absorption of Q-LHD was observed in SKH1 mice for 3 h under different doses. From the results, we confirmed that Q-LHD was absorbed mostly into the ileum of small intestine containing intestinal bile acid transporter as observed in TEM and molecular imaging system. Our designed nanoparticles could be administered orally for bio-imaging and studying the bio-distribution of drug. (C) 2012 Elsevier Ltd. All rights reserved.